(HealthDay News) – A diabetes-related genetic risk score is associated with a history of gestational diabetes, but it does not predict progression to type 2 diabetes in women with or without prior gestational diabetes, according to research published online Nov. 22 in Diabetes Care.
Shannon D. Sullivan, of the MedStar Washington Hospital Center in Washington, DC, and colleagues performed genotyping and calculated genetic risk scores for a subset of women with prediabetes enrolled in the Diabetes Prevention Program trial. The participants were randomly assigned to treatment with placebo, metformin, or intensive lifestyle intervention. The association between genetic risk score and progression to diabetes and treatment was assessed.
The researchers found that β-cell function was decreased, and genetic risk score was increased, in women with a history of gestational diabetes. However, genetic risk score was not associated with risk of progression to diabetes, or response to treatment, in women at high risk for diabetes, with or without gestational diabetes.
“The genetic risk score was positively associated with a history of gestational diabetes mellitus; however, the genetic risk score did not predict progression to diabetes or modulate response to intervention,” the authors write.
Pharmaceutical and other companies provided medications, materials, and/or equipment for the study. Several authors disclosed financial ties to pharmaceutical companies.